68Ga-PSMA PET/CT检测新诊断前列腺癌转移及其与改良D'Amico风险分类的关系
本研究回顾性分析356例新诊断前列腺癌患者,在治疗前行68Ga-PSMA PET/CT并按PSMA-RADS v1.0判读,按改良D'Amico分类分组。结果显示高危组任何转移检出率47.7%,中危组仅盆腔淋巴结转移3.7%,低危组无转移;基于49例病理,盆腔淋巴结转移诊断灵敏度71.4%、特异度100%。结论支持高危患者常规使用,中危有限,低危无用。
要点
- 高危组任何转移检出率47.7%,中危组仅盆腔淋巴结转移3.7%,低危组无转移。
- 盆腔淋巴结转移诊断灵敏度71.4%、特异度100%、准确率95.9%。
- 推荐新诊断高危前列腺癌患者常规行68Ga-PSMA PET/CT。
核心结论
- 68Ga-PSMA PET/CT应常规用于新诊断高危前列腺癌患者,中危组使用有限,低危组无用。
研究设计与样本
- 回顾性评估356例治疗前接受68Ga-PSMA PET/CT的新诊断前列腺癌患者,按PSMA-RADS v1.0判读图像。
主要发现
- 中位PSA为16.42(1.29-7013)ng/ml,中位Gleason评分为8(范围6-10)。
- 低、中、高危组分别占3.7%、15.1%、81.2%。
- 125例(35.1%)检出淋巴结转移,其中48例转移局限于盆腔淋巴结。
- 高危组任何转移检出率47.7%,中危组仅盆腔淋巴结转移3.7%,低危组无任何转移。
关键数值与推荐
- 基于49例病理结果,盆腔淋巴结转移诊断灵敏度71.4%、特异度100%、准确率95.9%、阳性预测值100%、阴性预测值95.4%。
临床怎么用
- 对新诊断高危前列腺癌患者常规行68Ga-PSMA PET/CT以检测转移。
- 中危患者可选择性使用,低危患者不建议常规使用。
局限性
- 盆腔淋巴结转移诊断效能仅基于49例患者的组织病理学结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to investigate the diagnostic power of 68Ga-PSMA PET/CT in the detection of metastatic spread of newly diagnosed PCa, and evaluate the relationship with modified D'Amico risk classification. METHODS: We evaluated newly diagnosed PCa patients who underwent 68Ga-PSMA PET/CT prior to therapy. All images were interpreted retrospectively and areas of abnormally increased tracer uptake were documented according to PSMA-RADS version 1.0 system. Patients were divided into risk groups as low, intermediate, or high risk, according to a modification in D'Amico classification system as ISUP grade 3 tumors were included to high-risk group. 68Ga-PSMA PET/CT findings were compared among risk groups as well as PSA levels, clinical T stages, and ISUP grades. RESULTS: A total of 356 patients were included to the study with a median PSA level was 16.42 (1.29-7013) ng/ml and median Gleason score was 8 (range: 6-10). Of these, 13(3.7%), 54 (15.1%), and 289 (81.2%) were in the low-, intermediate-, and high-risk groups, respectively. Lymph node metastases were detected in 125 (35.1%) patients, and in 48 of them, metastasis was limited to pelvic lymph nodes (PLN). Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated as 71.4%, 100%, 95.9%, 100%, and 95.4%, respectively for the detection of PLN, based on histopathological results of 49 patients. Overall, any metastasis was detected in 47.7% of high-risk patients, while only PLN metastases were defined in 3.7% intermediate-risk patients and none of low-risk patients had any kind of metastasis. CONCLUSION: This study revealed that 68Ga-PSMA PET/CT should be routinely used in newly diagnosed high-risk PCa patients; whereas it seems to be of limited use for intermediate-risk group and useless for the low-risk group.
引用
- Simsek DH, Sanli Y, Engin MN, et al. Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D'Amico risk classification. Eur J Nucl Med Mol Imaging. 2020. PMID: 32789600. doi:10.1007/s00259-020-04995-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。